| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Cartesian Therapeutics, Inc. (RNAC) has 13 insiders with recent SEC Form 4 filings, including 25 buys and 5 sells. RNAC is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 8.65M | $74.70M | - | |
| 10% | 511.6K | $4.42M | - | |
| CEO | 323.5K | $2.80M | - | |
| CFO | 121.2K | $1.05M | - | |
| Other | 94.2K | $814.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 4, 2024 | Springer Timothy A49 | Director, 10% Owner | Buy | 205,721 | $20.87 | $4,293,544.83 | +0.3% | -31.0% | -58.4% | |
| Aug 12, 2024 | Barabe Timothy C49 | Director | Buy | 7,500 | $12.70 | $95,250.00 | +52.6% | +55.7% | -10.8% | |
| Aug 12, 2024 | Springer Timothy A49 | Director, 10% Owner | Buy | 8,016 | $12.72 | $101,967.53 | +229.5% | +55.7% | -10.8% | |
| Mar 18, 2024 | Springer Timothy A49 | Director, 10% Owner | Buy | 19,044 | $0.60 | $11,397.83 | - | +23.0% | -23.0% | |
| Mar 18, 2024 | Springer Timothy A49 | Director, 10% Owner | Buy | 18,400 | $0.62 | $11,442.24 | +1.9% | +23.0% | -23.0% | |
| Mar 15, 2024 | Springer Timothy A49 | Director, 10% Owner | Buy | 1,185,872 | $0.56 | $666,221.97 | +2.0% | +68.2% | -9.2% | |
| Sep 25, 2023 | Brunn Carsten86 | President And CEO | Sell | 2,932 | $1.06 | $3,107.92 | -0.4% | -30.9% | -50.2% | |
| Sep 25, 2023 | Traber Peter G59 | Chief Medical Officer | Sell | 705 | $1.06 | $747.30 | -0.2% | -30.9% | -50.2% | |
| Jan 5, 2023 | Johnston Lloyd P.74 | Chief Operations Officer | Sell | 3,372 | $1.13 | $3,808.00 | -1.3% | +12.1% | -46.3% | |
| Jan 5, 2023 | Kishimoto Takashi Kei73 | Chief Scientific Officer | Sell | 3,392 | $1.13 | $3,830.23 | -0.5% | +12.1% | -46.3% |